First patient in Cohort four has been treated with TTX-MC138 Ten patients have been treated with TTX-MC138 at escalating dose levels Additional patients being evaluated for eligibility for expanded enrollment No significant safety or dose limiting toxicities have been reported BOSTON,...
Read More Details
Finally We wish PressBee provided you with enough information of ( TransCode Therapeutics Announces Initial Dosing in Fourth Cohort of Phase 1 Clinical Trial with TTX-MC138 )
Also on site :
- Beloved brand ends controversial 50 cent fee on popular breakfast staple as it gets ahead of Waffle House
- Wimbledon: Naomi Osaka loses to Anastasia Pavlyuchenkova in the 3rd round
- Should You Expect USPS Mail Delivery on July 4th?